NCT03967977 2026-04-17
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
BeOne Medicines
Phase 3 Active not recruiting
BeOne Medicines
National Cancer Institute (NCI)
Seagen Inc.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Hoffmann-La Roche
Mabwell (Shanghai) Bioscience Co., Ltd.
RemeGen Co., Ltd.
National Cancer Institute (NCI)
Shanghai Junshi Bioscience Co., Ltd.